Table 3.

Effect of Infliximab treatment on cell death markers in Zaprinast-treated retinal explants

	TUNEL-positive cells (%)				caspase-3 positive cells (%)				PAR content (CF)
Layer	C	Z100	INF	Z100 + INF	C	Z100	INF	Z100 + INF	C	Z100	INF	Z100 + INF
ONL	0.3 ± 0.1	3.0 ± 1.1a	0.4 ± 0.2b	0.2 ± 0.1c	0.07 ± 0.04	0.2 ± 0.1	0.01 ± 0.01b	0.04 ± 0.03c	7,647 ± 676	22,925 ± 5111a	15,982 ± 2,019	24,970 ± 1,807d,e
INL	1.1 ± 0.2	2.5 ± 0.4a	0.8 ± 0.3b	1.1 ± 0.3	0.2 ± 0.1	2.1 ± 0.3a	0.4 ± 0.3b	0.4 ± 0.1c	7,019 ± 1,163	9,348 ± 2,288	11,156 ± 1,879	21,511 ± 2,251c,d,e
GCL	0.7 ± 0.1	2.0 ± 0.4a	0.6 ± 0.3b	1.0 ± 0.3	0.6 ± 0.3	1.3 ± 0.2a	0.3 ± 0.1	0.6 ± 0.2c	9,891 ± 2,011	10,019 ± 2,212	10,204 ± 1,496	17,134 ± 2,274c,e

Note: Kruskal-Wallis test and Dunn’s Multiple Comparisons were used. Values different from control are shown by ^a(P <0.05). Superscripts represent statistical differences (P <0.05) between ^bZ100 and INF; ^cZ100 and Z100 + INF; ^dINF and Z100 + INF; ^eC and Z100 + INF respectively. ONL: outer nuclear layer; INL: inner nuclear layer; GCL: ganglion nuclear layer; PAR, poly(ADP-ribose) polymers; C: control; Z100: 100 μM Zaprinast; INF: 2 μg/mL Infliximab; Z100 + INF: 100 μM Zaprinast with 2 μg/mL Infliximab; CF: corrected fluorescence.